Skip to main content
Erschienen in: World Journal of Surgery 4/2016

01.04.2016 | Original Scientific Report

The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution

verfasst von: Se-Jin Baek, Hyuk Hur, Byung-Soh Min, Seung-Hyuk Baik, Kang-Young Lee, Nam-Kyu Kim

Erschienen in: World Journal of Surgery | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Bone metastasis in patients with colorectal cancer (CRC) is very rare, and data are extremely lacking. We aimed to evaluate the characteristics of bone metastasis in patients with CRC.

Materials and methods

We performed a chart review of 63 patients (1.1 %) with bone metastasis among 5479 patients who underwent surgery for CRC.

Results

Most patients were stage 3 (17.5 %) or 4 (73.0 %), and 32 patients (50.8 %) were diagnosed with bone metastasis at initial diagnoses of CRC. Thirty-one patients developed bone metastasis during the follow-up period with median 10.1-month interval. PET–CT was most frequently used for the diagnosis of bone metastasis (71.4 %), and the spine was the most commonly involved site (77.8 %). Most patients had multiple bone metastases (73.0 %) and other metastases (87.3 %). Bone pain was the most common skeletal-related event (25.4 %), and patients were treated with radiation (25.4 %), surgery (14.3 %), or bisphosphonate (6.3 %). The median survival time was 17.8 months, and the 5-year survival rate was 5.7 %. In the multivariate analysis, the risk factors for survival included initial bone metastasis (hazard ratio [HR] 3.03; P < 0.001) and bone metastasis from colon cancer (HR 1.87; P = 0.04).

Conclusion

Bone metastasis in patients with CRC is extremely rare and shows poor prognosis.
Literatur
1.
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMed O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMed
2.
Zurück zum Zitat Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113CrossRefPubMed Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108–113CrossRefPubMed
3.
Zurück zum Zitat Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ (2009) Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 9:274PubMedCentralCrossRefPubMed Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ (2009) Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 9:274PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254CrossRefPubMed Khattak MA, Martin HL, Beeke C et al (2012) Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 11:247–254CrossRefPubMed
6.
7.
Zurück zum Zitat Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001–1010CrossRefPubMed Bundred NJ, Campbell ID, Davidson N et al (2008) Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112:1001–1010CrossRefPubMed
8.
Zurück zum Zitat De Marinis F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4:1280–1288CrossRefPubMed De Marinis F, Eberhardt W, Harper PG et al (2009) Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 4:1280–1288CrossRefPubMed
9.
Zurück zum Zitat Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMed Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882CrossRefPubMed
10.
11.
Zurück zum Zitat Ganry O, Lapotre-Ledoux B, Fardellone P, Dubreuil A (2008) Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 23:467–473CrossRefPubMed Ganry O, Lapotre-Ledoux B, Fardellone P, Dubreuil A (2008) Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 23:467–473CrossRefPubMed
12.
Zurück zum Zitat Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581CrossRefPubMed Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581CrossRefPubMed
13.
Zurück zum Zitat Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799–802PubMedCentralCrossRefPubMed Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799–802PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Nozue M, Oshiro Y, Kurata M et al (2002) Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 9:109–112PubMed Nozue M, Oshiro Y, Kurata M et al (2002) Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 9:109–112PubMed
15.
Zurück zum Zitat Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D (2007) Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 16:539–542CrossRef Heras P, Karagiannis S, Kritikos K, Hatzopoulos A, Mitsibounas D (2007) Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 16:539–542CrossRef
16.
Zurück zum Zitat Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMed Fong Y, Cohen AM, Fortner JG et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15:938–946PubMed
17.
Zurück zum Zitat Rotolo N, De Monte L, Imperatori A, Dominioni L (2007) Pulmonary resections of single metastases from colorectal cancer. Surg Oncol 16:S141–S144CrossRefPubMed Rotolo N, De Monte L, Imperatori A, Dominioni L (2007) Pulmonary resections of single metastases from colorectal cancer. Surg Oncol 16:S141–S144CrossRefPubMed
18.
Zurück zum Zitat Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR (2011) Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol 2:326–328PubMedCentralCrossRefPubMed Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR (2011) Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol 2:326–328PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Santini D, Tampellini M, Vincenzi B et al (2012) Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:2072–2077CrossRefPubMed Santini D, Tampellini M, Vincenzi B et al (2012) Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 23:2072–2077CrossRefPubMed
20.
Zurück zum Zitat Fairchild A, Barnes E, Ghosh S et al (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75:1501–1510CrossRefPubMed Fairchild A, Barnes E, Ghosh S et al (2009) International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int J Radiat Oncol Biol Phys 75:1501–1510CrossRefPubMed
21.
Zurück zum Zitat Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317–7325CrossRefPubMed Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317–7325CrossRefPubMed
22.
23.
Zurück zum Zitat Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405CrossRefPubMed Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405CrossRefPubMed
24.
Zurück zum Zitat Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMed Body JJ, Diel IJ, Bell R et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312CrossRefPubMed
25.
Zurück zum Zitat Hattori S, Miyakawa H, Okuda K, Kudo K, Noguchi T (2004) Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases. Gan To Kagaku Ryoho 31:271–274PubMed Hattori S, Miyakawa H, Okuda K, Kudo K, Noguchi T (2004) Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases. Gan To Kagaku Ryoho 31:271–274PubMed
Metadaten
Titel
The Characteristics of Bone Metastasis in Patients with Colorectal Cancer: A Long-Term Report from a Single Institution
verfasst von
Se-Jin Baek
Hyuk Hur
Byung-Soh Min
Seung-Hyuk Baik
Kang-Young Lee
Nam-Kyu Kim
Publikationsdatum
01.04.2016
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 4/2016
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3296-x

Weitere Artikel der Ausgabe 4/2016

World Journal of Surgery 4/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.